EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Enfortumab vedotin plus pembrolizumab in treatment‐naïve metastatic urothelial carcinoma patients: An Austrian real‐world analysis

Dora Niedersuess-Beke iD, Karl Mayrhofer, Johanna Krauter, Johannes Franke, Dominic Vais, Maximillian Pallauf, David Kiesl, Ferdinand Luger, Jacob Pfuner, Angelika Terbuch, Thomas Bauernhofer, Jasmin Spielgelberg und 19 weitere

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70203 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Dora Niedersuess-Beke und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I., Centre for Oncology and Haematology, Vienna Healthcare Group, Ottakring, Vienna, Austria. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Transitional Cell, Antibodies, Monoclonal. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Astellas Pharma GmbH, Astellas Pharma Deutschland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody‐drug conjugates (ADCs) and immunotherapy have changed the treatment landscape for locally advanced and metastatic urothelial carcinoma (la/mUC). Clinical trials have demonstrated the superiority of enfortumab vedotin (EV) combined with pembrolizumab (P) over chemotherapy. This retrospective, multicentre Austrian registry analysis evaluated the effectiveness and safety of EV + P in treatment‐naïve la/mUC patients in a real‐world setting. This study included 203 first‐line EV + P treated patients from 20 Austrian centres. The majority were male (77.3%), with a median age of 70 years (range, 26–92), while 33.5% were ≥75 years. Comorbidities were common, with 25.1% having a Charlson Comorbidity Index (CCI) ≥ 5, and 46.3% moderate to severe renal impairment. Among 195 evaluable patients, the objective response rate (ORR) was 63.6% (95% CI, 56.6–70.0), including 21.5% complete responses and 42.1% partial responses. Disease control was achieved in 75.4% (95% CI, 68.9–80.9). Median progression‐free survival (PFS) and overall survival (OS) were not reached after a median follow‐up of 5.8 months. Poor outcomes were associated with ECOG PS >2 (PFS, p = .003; OS, p < .001) and CCI ≥5 (PFS, p = .011; OS, p = .08). EV + P was generally well tolerated; grade ≥3 treatment‐related adverse events occurred in 38.4% of patients and immune‐related adverse events in 19.2%. Limitations of this study include its retrospective design and short follow‐up. These findings support the clinical use of EV + P as first‐line treatment for la/mUC, demonstrating substantial effectiveness and manageable toxicity in a large real‐world population, including elderly and comorbid patients. Extended follow‐up is warranted to determine long‐term survival and predictive markers of response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Transitional CellAntibodies, MonoclonalUrologic NeoplasmsUrinary Bladder NeoplasmsHumansMaleFemaleAgedMiddle AgedAged, 80 and overRetrospective StudiesAustriaAdult

Stichwörter der Autor:innen

enfortumab vedotinmetastatic urothelial carcinomapembrolizumabreal‐world evidenceregistry

Substanzen

Antibodies, Monoclonal, Humanizedpembrolizumabenfortumab vedotinAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Internal Medicine I., Centre for Oncology and Haematology, Vienna Healthcare Group, Ottakring, Vienna, Austria.
  • Department of Urology, Medical University of Vienna, Vienna, Austria.
  • Department of Internal Medicine Oncology and Haematology, State Hospital Klagenfurt, Klagenfurt, Austria.
  • Department of Urology, University Hospital Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria.
  • Department of Internal Medicine I with Haematology, Medical Oncology, Ordensklinikum Linz Elisabethinen, Linz, Austria and Johannes Kepler University, Linz, Austria.
  • Department of Urology, Ordensklinikum Linz Elisabethinen, Linz, Austria.

ORCID-Profile: Dora Niedersuess-Beke, Simon Peter Gampenrieder, Renate Pichler

Förderung

  • Astellas Pharma GmbH
  • Astellas Pharma Deutschland

Zitieren

APA

Niedersuess-Beke, D., Mayrhofer, K., Krauter, J., Franke, J., Vais, D., Pallauf, M., Kiesl, D., Luger, F., Pfuner, J., Terbuch, A., Bauernhofer, T., Spielgelberg, J., Banner, A., Aufderklamm, S., Wiesinger, C., Schnabel, S., Gampenrieder, S. P., Mühlmann, J., Vallet, S., …, & Pichler, R. (2026). Enfortumab vedotin plus pembrolizumab in treatment‐naïve metastatic urothelial carcinoma patients: An Austrian real‐world analysis. International Journal of Cancer. https://doi.org/10.1002/ijc.70203

Vancouver

Niedersuess-Beke D, Mayrhofer K, Krauter J, Franke J, Vais D, Pallauf M, et al. Enfortumab vedotin plus pembrolizumab in treatment‐naïve metastatic urothelial carcinoma patients: An Austrian real‐world analysis. International Journal of Cancer. 2026. doi:10.1002/ijc.70203

BibTeX
@article{NiedersuessBeke2026,
  author = {Niedersuess-Beke, Dora and Mayrhofer, Karl and Krauter, Johanna and Franke, Johannes and Vais, Dominic and Pallauf, Maximillian and Kiesl, David and Luger, Ferdinand and Pfuner, Jacob and Terbuch, Angelika and Bauernhofer, Thomas and Spielgelberg, Jasmin and Banner, Andreas and Aufderklamm, Stefan and Wiesinger, Clemens and Schnabel, Susanne and Gampenrieder, Simon Peter and Mühlmann, Josef and Vallet, Sonia and Weibrecht, Sabine and Stoiber, Franz and Andalibi, Haleh and Fajkovic, Harun and Taghizadeh, Hossein and Miechowiecki, Jan and Taedcke, Roman and Heintel, Daniel and Shariat, Shahrokh F and Pichler, Martin and Hilbe, Wolfgang and Pichler, Renate},
  title = {Enfortumab vedotin plus pembrolizumab in treatment‐naïve metastatic urothelial carcinoma patients: An Austrian real‐world analysis},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70203}
}
Kostenlos starten →